ReviewNature protocols2024
Functionalized tetrahedral DNA frameworks for the capture of circulating tumor cells.
Review in Nature protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 36 citations in OpenAlex.
- Advances in DNA nanostructures for pathogenic microorganisms.Materials today. Bio · 2026Review
- Self-Propelled Magnetic Micromotor-Functionalized DNA Tile System for Autonomous Capture of Circulating Tumor Cells in Clinical Diagnostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Highly Ordered DNA Framework Interface Enables Efficient Enzymatic Oligonucleotide Synthesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Enzyme-free quantification of breast cancer-derived exosomes via cubic DNA nanostructure-enhanced hybridization chain reaction.Mikrochimica acta · 2025Article
- Identification of multiple genomic alterations and prediction of neoantigens from circulating tumor cells at the single-cell level.Nature communications · 2025Article
- Engineered platelet-derived exosomal spheres for enhanced tumor penetration and extended circulation in melanoma immunotherapy.Acta pharmaceutica Sinica. B · 2025Article
- Cartilage-Penetrating Framework Nucleic Acid Nanoparticles Ameliorate Osteoarthritis by Promoting Drug Delivery and Chondrocyte Uptake.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Advances in Cell Separation: Harnessing DNA Nanomaterials for High-Specificity Recognition and Isolation.Chem & bio engineering · 2025Review
- Current Understanding and Translational Prospects of Tetrahedral Framework Nucleic Acids.JACS Au · 2025Review
- Precise control of transmembrane current via regulating bionic lipid membrane composition.Science advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Identification and characterization of circulating tumor cells (CTCs) from blood samples of patients with cancer can help monitor parameters such as disease stage, disease progression and therapeutic efficiency. However, the sensitivity and specificity of current multivalent approaches used for CTC capture is limited by the lack of control over the ligands' position. In this Protocol Update, we describe DNA-tetrahedral frameworks anchored with aptamers that can be configured with user-defined spatial arrangements and stoichiometries. The modified tetrahedral DNA frameworks, termed 'n-simplexes', can be used as probes to specifically target receptor-ligand interactions on the cell membrane. Here, we describe the synthesis and use of n-simplexes that target the epithelial cell adhesion molecule expressed on the surface of CTCs. The characterization of the n-simplexes includes measuring the binding affinity to the membrane receptors as a result of the spatial arrangement and stoichiometry of the aptamers. We further detail the capture of CTCs from patient blood samples. The procedure for the preparation and characterization of n-simplexes requires 11.5 h, CTC capture from clinical samples and data processing requires ~5 h per six samples and the downstream analysis of captured cells typically requires 5.5 h. The protocol is suitable for users with basic expertise in molecular biology and handling of clinical samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.